Finance

Lists
Why is SABS down 2.84%?
Dive Deeper
SABS:NASDAQ
SAB Biotherapeutics Inc
$3.08
-2.84%
(-0.090) 1D
Oct 1, 2:38:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for SABS...
Open
$3.15
High
$3.22
Low
$3.04
Mkt. cap
280.24M
Avg. vol.
510.70K
Volume
236.56K
52-wk high
$5.15
52-wk low
$1.94
EPS
-$0.63
Beta
0.53
Shares outstanding
90.99M
No. of employees
86
Open
$3.15
High
$3.22
Low
$3.04
Mkt. cap
280.24M
Avg. vol.
510.70K
Volume
236.56K
52-wk high
$5.15
52-wk low
$1.94
EPS
-$0.63
Beta
0.53
Shares outstanding
90.99M
No. of employees
86
News stories
From web sources and news partners
About SAB Biotherapeutics Inc
CEO-
Employees86
Founded2014
HeadquartersMiami Beach, Florida, United States
SectorBiotechnology
Websitesab.bio
Analyst ratings
Based on 3 analysts giving stock ratings to SABS in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for SABS in the last 3 months.
Highest
Current $3.08
$15.00 (+387.01%)
Average
$12.67 (+311.36%)
Lowest
$10.00 (+224.68%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eliana Merle
Barclays
Buy
Maintained
$13.00
+322.1%
08/07/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$10.00
+224.7%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$15.00
+387%
08/07/2026
Keay Nakae
Chardan Capital
Buy
Reiterated
$16.00
+419.5%
06/16/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$6.00
+94.8%
06/16/2026
Samantha Semenkow
Citi
Buy
Reiterated
$11.00
+257.1%
06/15/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
$14.00
+354.5%
06/15/2026
Roger Song
Jefferies
Buy
Initiated
$11.00
+257.1%
05/20/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$15.00
+387%
05/13/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$13.00
+322.1%
04/02/2026
Michael Yee
UBS
Buy
Maintained
$7.00
+127.3%
02/25/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
8.97M
9.73M
13.40M
16.17M
Cost of revenue
8.97M
9.73M
13.40M
16.17M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.71M
6.04M
6.60M
7.20M
Operating expense
3.71M
6.04M
6.60M
7.20M
Total operating expenses
12.68M
15.77M
20.00M
23.38M
Operating income
-12.68M
-15.77M
-20.00M
-23.38M
Other non operating income
57.51M
-1.73M
144.40K
-761.00K
EBT including unusual items
45.45M
-16.86M
-18.87M
-22.49M
EBT excluding unusual items
45.45M
-16.86M
-18.87M
-22.49M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
45.45M
-16.86M
-18.87M
-22.49M
Net profit margin
-
-
-
-
Earnings per share
-
-0.41
-
-0.28
Interest and investment income
655.23K
700.74K
1.05M
1.71M
Interest expense
-43.29K
-63.46K
-62.74K
-62.00K
Net interest expenses
611.94K
637.28K
984.45K
1.65M
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.91M
-15.01M
-19.25M
-22.54M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps